Targeting minimal residual disease: a path to cure?
Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disea...
| Príomhchruthaitheoirí: | , , , |
|---|---|
| Rannpháirtithe: | |
| Formáid: | Alt |
| Teanga: | en_US |
| Foilsithe / Cruthaithe: |
Nature Publishing Group
2018
|
| Rochtain ar líne: | http://hdl.handle.net/1721.1/118912 https://orcid.org/0000-0001-5223-9433 |